
zzso tumors are zzso with two-thirds of patients responding to zzso combination chemotherapy with zzso zzso zzso and zzso zzso zzso a new zzso and zzso agent has shown high response rates in zzso zzso zzso We investigated this drug in zzso zzso tumors zzso and mixed zzso zzso after prior zzso chemotherapy and radiation zzso 

In a prospective zzso zzso phase II trial patients were treated with zzso 150 zzso on days zzso in cycles of 28 days for 12 zzso zzso patients had a recurrence after prior zzso chemotherapy, with measurable and enhancing disease as shown by magnetic resonance zzso zzso and all responses were centrally zzso 

zzso eligible patients were zzso In four patients the pathology review did not confirm the presence of an zzso or zzso Twelve of 24 patients zzso zzso confidence zzso zzso zzso to zzso zzso for response to zzso zzso chemotherapy had responded to zzso zzso was in general well zzso the most frequent zzso were zzso One patient discontinued treatment due to zzso In seven of 28 patients zzso zzso zzso zzso to zzso with zzso confirmed zzso an objective response to zzso was zzso Median time to progression for responding patients was zzso zzso After 6 and 12 months from the start of treatment, zzso and zzso of patients, respectively, were still free from zzso 

zzso may be regarded as the preferred zzso treatment in zzso after failure of zzso zzso Further studies on zzso in zzso are zzso 

